Field Safety Notices: 16 to 20 June 2025
List of Field Safety Notices from 16 to 20 June 2025.
-
-
Transparency data: Medicines and Healthcare products Regulatory Agency spending over £25,000: 2025 to 2026
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
-
Transparency data: Medicines and Healthcare products Regulatory Agency GPC spending over £500: 2024-25
MHRA transactions over £500 made using the government procurement card (GPC).
-
MHRA Safety Roundup: June 2025
Summary of the latest safety advice for medicines and medical device users
-
Transparency data: Medicines and Healthcare products Regulatory Agency GPC spending over £500: 2025-26
MHRA transactions over £500 made using the government procurement card (GPC).
-
Transparency data: Medicines and Healthcare products Regulatory Agency spending over £25,000: 2024 to 2025
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
-
Guidance: AI Airlock Background
Background information for MHRA AI Airlock launched in Spring 2024 and is the MHRA’s first regulatory sandbox for AI as a Medical Device (AIaMD) products.
-
AI breakthroughs drive expansion of ‘Airlock’ testing programme to support AI-powered healthcare innovation
MHRA opens second round of applications to test cutting-edge AI medical technologies following successful pilot phase.
-
Guidance: AI Airlock Phase 2 application
The call for application for phase 2 of the AI Airlock is now open. This page contains information on eligibility and how to apply
-
MHRA approves UK’s first anti-PD-1 monoclonal antibody for treatment of aggressive form of lung cancer
As with all products, we will keep its safety under close review
-
Guidance: The Innovative Devices Access Pathway (IDAP)
The Innovative Devices Access Pathway (IDAP) pilot is designed to accelerate the development of innovative medical devices that meet an unmet clinical need in the NHS and support their integration into the UK market.
-
IXCHIQ Chikungunya vaccine: temporary suspension in people aged 65 years or older
The Commission on Human Medicines (CHM) has temporarily restricted use of the IXCHIQ Chikungunya vaccine in people aged 65 years and over following very rare fatal reactions reported globally. This is a precautionary measure while the MHRA conducts a safety review. The IXCHIQ vaccine will be available on the UK market from 18 June 2025.